UbiVac
UbiVac is a clinical-stage immunotherapy company pioneering "Dark Genome-derived" cancer immunotherapies, with its lead agent DPV-001 targeting "Cancer's Dark Matter" – newly discovered non-mutated shared alternative cancer neoantigens. Their unique platform technology aims to overcome the limitations of current cancer treatments by stimulating a broad immune response against a wide spectrum of cancer types. Recent clinical data shows DPV-001 in combination with anti-PD-1 therapy significantly triples response rates and duration of response in patients with head and neck squamous cell carcinoma. UbiVac possesses in-house GMP manufacturing capabilities and is leveraging machine learning and AI to discover new cancer targets and tailor treatment regimens, positioning them to revolutionize cancer treatment.
UbiVac
UbiVac is a clinical-stage immunotherapy company pioneering "Dark Genome-derived" cancer immunotherapies, with its lead agent DPV-001 targeting "Cancer's Dark Matter" – newly discovered non-mutated shared alternative cancer neoantigens. Their unique platform technology aims to overcome the limitations of current cancer treatments by stimulating a broad immune response against a wide spectrum of cancer types. Recent clinical data shows DPV-001 in combination with anti-PD-1 therapy significantly triples response rates and duration of response in patients with head and neck squamous cell carcinoma. UbiVac possesses in-house GMP manufacturing capabilities and is leveraging machine learning and AI to discover new cancer targets and tailor treatment regimens, positioning them to revolutionize cancer treatment.